ACRV insider trading
NasdaqGM HealthcareAcrivon Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Company website: acrivon.com
ACRV insider activity at a glance
FilingIQ has scored 134 insider transactions for ACRV since Nov 14, 2022. The most recent filing in our index is dated Apr 22, 2026.
Across the full history, 6 open-market purchases
and 10 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ACRV insider trades is 54.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ACRV Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ACRV
Frequently asked
- How many insider trades does FilingIQ track for ACRV?
- FilingIQ tracks 134 Form 4 insider transactions for ACRV (Acrivon Therapeutics, Inc.), covering filings from Nov 14, 2022 onwards. 11 of those were filed in the last 90 days.
- Are ACRV insiders net buyers or net sellers?
- Across the full Form 4 history for ACRV, 6 transactions (4%) were open-market purchases and 10 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ACRV insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ACRV in?
- Acrivon Therapeutics, Inc. (ACRV) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $47.33M.
Methodology & sources
Every ACRV insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.